A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX New Seed Process (NSP) Administered Concomitantly With M-M-R II
Phase of Trial: Phase III
Latest Information Update: 05 Jul 2019
Price : $35 *
At a glance
- Drugs Varicella zoster virus vaccine live (Primary) ; Measles mumps and rubella virus vaccine
- Indications Chickenpox; Varicella zoster virus infections
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 20 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Mar 2015 Planned End Date changed from 1 May 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
- 18 Jan 2015 Planned End Date changed from 1 Oct 2015 to 1 May 2015 as reported by ClinicalTrials.gov.